The IL-4/13-induced production of M2 chemokines by human lung macrophages is enhanced by adenosine and PGE

Adenosine Chemokines Interleukin-13 Interleukin-4 Lung macrophages Phosphodiesterase 4 Roflumilast prostaglandin E(2)

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 13 11 2023
revised: 12 01 2024
accepted: 15 01 2024
medline: 25 1 2024
pubmed: 25 1 2024
entrez: 24 1 2024
Statut: aheadofprint

Résumé

Lung macrophages (LMs) are critically involved in respiratory diseases. The primary objective of the present study was to determine whether or not an adenosine analog (NECA) and prostaglandin E Primary macrophages isolated from resected human lungs were incubated with NECA, PGE Exposure to IL-4 (10 ng/mL) and IL-13 (50 ng/mL) was associated with greater M2a chemokine production but not PGE NECA and PGE

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Lung macrophages (LMs) are critically involved in respiratory diseases. The primary objective of the present study was to determine whether or not an adenosine analog (NECA) and prostaglandin E
EXPERIMENTAL APPROACH METHODS
Primary macrophages isolated from resected human lungs were incubated with NECA, PGE
KEY RESULTS RESULTS
Exposure to IL-4 (10 ng/mL) and IL-13 (50 ng/mL) was associated with greater M2a chemokine production but not PGE
CONCLUSIONS CONCLUSIONS
NECA and PGE

Identifiants

DOI: 10.1016/j.intimp.2024.111557 PMID: 38266451
pubmed: 38266451
pii: S1567-5769(24)00075-4
doi: 10.1016/j.intimp.2024.111557
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111557

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Marion Brollo (M)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France.

Hélène Salvator (H)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France.

Stanislas Grassin-Delyle (S)

Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France; Department of Airway Diseases, Thoracic surgery, Foch Hospital, Suresnes, France.

Mathieu Glorion (M)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; INSERM U1173, Infection & Inflammation, Département de Biotechnologie de la Santé, Université Paris-Saclay, Montigny-le-Bretonneux, France.

Delphyne Descamps (D)

VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, Jouy-en-Josas, France.

Amparo Buenestado (A)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France.

Emmanuel Naline (E)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France.

Hermann Tenor (H)

TOPADUR Pharma AG, Schlieren, Switzerland.

Angelica Tiotiu (A)

Department of Pulmonary Medicine, University Hospital Saint-Luc, Institut of Experimental and Clinical Research (IREC), University of Louvain, Brussels, Belgium.

Philippe Devillier (P)

Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France. Electronic address: p.devillier@hopital-foch.com.

Classifications MeSH